ArticleScience advances2025
Pressure-driven microinjection (PMI) of porous-coated balloon for ultrafast endoluminal drug delivery across biological barriers.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Itaconate and its derivatives in human health and diseases.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological barriers play a crucial role in safeguarding the human body against pathogens yet pose severe challenges to efficient delivery of therapeutic drugs. Here, we introduce a pressure-driven microinjection (PMI) strategy for the robust and versatile delivery of functional species against biological barriers. With the benefits of elastic porous coating, this strategy enables the capillary suction of drug solutions, localized delivery, and ultrafast penetration through biological barriers by gentle pressure treatment. The penetration capacity is demonstrated by an unprecedented depth (~150 micrometers) of bovine serum albumin (66.4 kilodaltons) across aortic vessels under pressing for only 60 seconds. This spongy coating-based PMI technique can be integrated with medical balloon devices, offering endoluminal treatment within blood vessels, tracheas, and intestines. The in vivo evaluation indicated efficient trans-vascular delivery of 4-octyl itaconate, markedly reducing neointima hyperplasia. This PMI strategy provides a crucial insight for penetrative drug delivery across complex biological barriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.